MedTrace Logo

Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.

NCT00105092 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2007-05-01

No results posted yet for this study

Summary

Enzastaurin given daily to patients with non-small cell lung cancer who have failed at least one prior therapy.

Conditions

  • Non-Small-Cell Lung Carcinoma

Interventions

DRUG

Enzastaurin HCL

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Completion
2007-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00105092 on ClinicalTrials.gov